Navigation Links
China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call
Date:3/26/2008

NEW YORK, March 26 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia International, Inc. (OTC Bulletin Board: CYXI), a leading provider in the nutraceutical industry engaged in the development, manufacture and distribution of organic nutritional food products, supplements, and personal care products in China, today announced that Ms. Yingxia Jiao, CEO and Chairwoman of China Yingxia, will host a conference call to discuss the Company's financial results for the fourth quarter and full year ended December 31, 2007.

The conference call will take place at 9:00 a.m. Eastern Standard Time, on Monday, March 31, 2008. Anyone interested in participating should call 1-800- 762-8779 if calling within the United States, or 1-480-248-5081 if calling internationally, approximately 5 to 10 minutes prior to 9:00 a.m. There will be a playback available until April 8, 2008. To listen to the playback, please call 1-800-406-7325 if calling within the United States, or 1-303-590-3030 if calling internationally. Please use pass code 3861152 for the replay.

This call is being webcast by ViaVid Broadcasting. The webcast may be accessed at ViaVid's Web site at http://www.viavid.net .

About China Yingxia International, Inc.

China Yingxia International, Inc., through its 100%-owned subsidiary, Harbin Yingxia Industrial Group Co., Ltd. ('Yingxia'), is primarily engaged in the development, production and sales of health food products in China. Yingxia is located in the Province of Heilongjiang in mainland China. Yingxia's products include soybean-based foods and drinks, longgu golden millet enriched products, cactus-based herbal supplements, personal care products, Nestle products, and organic rice products.

Safe Harbor Statement

The statements contained herein that are not historical facts are 'forward-looking statements' within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as 'believes,' 'expects,' 'may,' 'will,' 'should,' or 'anticipates' or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact:

Peter Zhou

Tel: +1-212-232-0058


'/>"/>
SOURCE China Yingxia International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Medicine Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
2. China RuiTai International Holdings Retains CCG Elite for Investor Relations Services
3. China Medical Technologies Receives CE Mark for Two ECLIA Analyzers and 15 Reagents
4. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
5. China Nepstar Chain Drugstore Announces Dividend
6. Alsius Corporation Receives Regulatory Approval in China and Mexico
7. Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition
8. China Nepstar Chain Drugstore Reports 231.5% Increase in Net Income and Record Gross Margin of 48.5% for Fourth Quarter 2007
9. Flagship Global Health and China HealthCare Holdings Form Strategic Alliance
10. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
11. China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology ... Dr. Li completed his internship in internal medicine at the Emory University and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... now offering treatments for patients with sleep apnea and TMJ disorders. These conditions ... and physical health. Dr. Rassouli provides personalized care to reduce the risk of ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree ... planning services to communities throughout eastern Georgia, is embarking on a charity effort ... Heart disease kills more Americans every year than anything else, yet risk factors ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages ... Real Impact contest from Impact Teen Drivers and California Casualty. Entries from students ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer messages ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... 19, 2017 Shire plc (LSE: ... U.S. Food and Drug Administration (FDA) has acknowledged receipt ... Application (NDA) for SHP465, a long-acting, triple-bead, mixed amphetamine ... once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is ... 20, 2017, the designated Prescription Drug User Fee Act ...
(Date:1/19/2017)... The global  pacemaker market  is expected to reach USD ... Inc. The heightening prevalence of cardiac conditions coupled with the availability of medical ... addition, technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
Breaking Medicine Technology: